Drug pricing regime needs to be predictable, transparent: Sanofi

Drug pricing regime needs to be predictable, transparent: Sanofi
Press Trust of India New Delhi
Last Updated : May 03 2016 | 1:33 AM IST
The government must not place the entire burden of access to health care on the pharmaceutical sector alone, Sanofi India has said, while hitting out at more medicines being put under price control.

At the company’s annual general meeting held on April 29, Managing Director Shailesh Ayyangar said any pricing regime must be predictable and transparent.

“And must take into consideration the stringent requirements on the quality front that manufacturers have to adhere to for patient safety,” he told shareholders.

Also Read

In December 2015, the ministry of health and family welfare notified a National List of Essential Medicines, 2015, resulting in 100 new molecules being added and 70 being excluded from the earlier list of 2011.

Stating the company understands its responsibility of making and distributing affordable essential medicines to all sections of society, Ayyangar said “ceiling prices for some of these products have already been announced and your company has consequently reduced their prices with effect from April 2016”.

Despite the significant impact suffered by the company, owing to price cuts imposed by the government, sales of the firm grew by nearly double digits, due to domestic and export performance, Ayyangar said.

Embattled industrialist Vijay Mallya also ceased to be on the company’s board at the conclusion of this meeting.

Commenting on the retirement of Mallya, who is currently facing heat over the loan default by long-defunct Kingfisher Airlines, Ayyangar said: “Having been a director for over 42 years and chairman of the board for over 32 years, he felt it was right time for him to retire.”

Mallya leaves the board at a time when the company is financially strong with an impeccable record, he adds.

Mallya became a director of the company (then called Hoechst Pharmaceuticals Ltd) in December 1973.

Mallya became a director of the company (then called Hoechst Pharmaceuticals Ltd) in December 1973 and has been chairman of the board since December 1983.

*Subscribe to Business Standard digital and get complimentary access to The New York Times

Smart Quarterly

₹900

3 Months

₹300/Month

SAVE 25%

Smart Essential

₹2,700

1 Year

₹225/Month

SAVE 46%
*Complimentary New York Times access for the 2nd year will be given after 12 months

Super Saver

₹3,900

2 Years

₹162/Month

Subscribe

Renews automatically, cancel anytime

Here’s what’s included in our digital subscription plans

Exclusive premium stories online

  • Over 30 premium stories daily, handpicked by our editors

Complimentary Access to The New York Times

  • News, Games, Cooking, Audio, Wirecutter & The Athletic

Business Standard Epaper

  • Digital replica of our daily newspaper — with options to read, save, and share

Curated Newsletters

  • Insights on markets, finance, politics, tech, and more delivered to your inbox

Market Analysis & Investment Insights

  • In-depth market analysis & insights with access to The Smart Investor

Archives

  • Repository of articles and publications dating back to 1997

Ad-free Reading

  • Uninterrupted reading experience with no advertisements

Seamless Access Across All Devices

  • Access Business Standard across devices — mobile, tablet, or PC, via web or app

More From This Section

First Published: May 03 2016 | 12:14 AM IST

Next Story